Article Details

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

Retrieved on: 2021-06-04 10:30:00

Tags for this article:

Click the tags to see associated articles and topics

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC. View article details on hiswai:

Excerpt

INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up